Securing High-Value Pharmaceutical Shipments in Parcel and Courier Networks
Protect Patients Beyond the Manufacturing Floor As specialty medicines, biologics, cell and gene therapies, and other high-value products increasingly move through parcel and courier networks, pharmaceutical supply chains face new security, quality, and logistics challenges. […]
Data Integrity Guide: Spreadsheet Validation
Strengthen Spreadsheet Controls. Reduce Compliance Risk. Spreadsheets remain one of the most widely used tools across pharmaceutical operations, supporting everything from laboratory calculations and stability programs to equipment maintenance, quality systems, and product release decisions. […]
The Next Episode | What 13 Years of DSCSA Teach Us About NDC-12 and Pharmaceutical Interoperability
The Transactions Haven’t Changed. The Network Has. Flying home from the HDA Traceability Seminar last week, I saw some news from Philadelphia that put much of what we had spent the previous few days discussing […]
HDA 2026 Traceability Seminar: From Implementation to Interoperability
What comes next for DSCSA OPERATIONS AND INTEROPERABILITY Thirteen years after DSCSA became law, the industry’s focus is shifting from implementation to sustained operation. At the 2026 HDA Traceability Seminar, discussions increasingly centered on what […]
When Distribution Models Change Faster Than Controls: GLP-1, DTC, and the New Pharmaceutical Risk Landscape
Within this slide deck, you can explore how GLP-1 demand, telehealth, digital pharmacies, and direct-to-consumer distribution are reshaping the pharmaceutical supply chain and creating new patient safety and security challenges. Rx-360’s Ryan Kelly, Interim CEO […]
Strengthening Patient Safety Through Practical Supplier Quality Oversight | Insights from an Rx‑360 Supplier Quality Working Group Informal Survey
Ensuring patient safety depends on the integrity of global pharmaceutical supply chains—yet Supplier Quality professionals continue to face practical, structural challenges in how audits are conducted, documented, and leveraged for assurance. To better understand current practices, Rx‑360 […]
Supplier Assessment Questionnaire (SAQ) Guide
TURN INSIGHT INTO ACTION WITH THE RX‑360 SAQ GUIDE The Rx‑360 Supplier Assessment Questionnaire (SAQ) Guide provides a practical walkthrough of how to effectively use the SAQ within your supplier qualification program. Designed as a […]
What the 2026 EU GMP Annex 1 Update Means for Veterinary Product Supplier Qualification
2026 EU GMP Annex 1 Update Means for Veterinary Product Supplier Qualification The 2026 EU GMP Annex 1 changes mark a major regulatory shift, introducing a full separation between human and veterinary manufacturing requirements. As […]
What the 2026 EU GMP Annex 1 Update Means for Veterinary Product Supplier Qualification
The 2026 EU GMP Annex 1 changes mark a major regulatory shift, introducing a full separation between human and veterinary manufacturing requirements. As veterinary products move to their own dedicated GMP framework, supplier qualification processes must adapt to a dual‑system reality that increases oversight, complexity, and compliance risk.
Refer to the following analysis to learn more about the changes and how they impact the pharmaceutical industry.
Regulatory Split Between Human and Veterinary GMP (effective July 16, 2026)
Veterinary medicinal products will transition to new GMP regulations, specifically:
- Commission Implementing Regulation (EU) 2025/2091 (veterinary finished products)
- Commission Implementing Regulation (EU) 2025/2154 (active substances for veterinary medicinal products)
Impact on the Pharmaceutical Industry
- Dual Compliance Frameworks: Any company manufacturing both human and veterinary medicinal products must now comply with two different GMP systems instead of one unified Annex 1–based framework.
- Quality System Adjustments: Organizations will need to separate documentation, training, procedures, and qualification systems for human vs. veterinary production.
- Inspection & Audit Changes: Regulatory inspections for veterinary products will now follow the new implementing regulations rather than the human‑focused Annex 1 guidance, requiring updated readiness plans.
____________________
END OF ANNEX 1 APPLICABILITY FOR VETERINARY MEDICINAL PRODUCTS
Annex 1 (sterile manufacturing guidance) no longer applies to veterinary products after that date
IMPACT ON THE PHARMACEUTICAL INDUSTRY
Different Sterile Manufacturing Expectations: Veterinary sterile manufacturing will be governed by new rules, meaning companies may need to revalidate cleanrooms, sterilization processes, and aseptic operations under the new veterinary framework if they produce vet sterile products.
Operational Complexity: Facilities producing both human and vet sterile medicines must maintain two parallel sterility assurance approaches.
Increased Strategic and Operational Burden on Mixed‑Portfolio Manufacturers
The 2026 regulatory change requires organizations operating in both sectors to:
- Reassess facility layouts, quality systems, documentation controls, and product life‑cycle practices to align with the split regulatory routes.
- Manage the administrative and cost burden of maintaining compliance with two diverging sets of GMP expectations.
Impact on the pharmaceutical industry
- Higher Costs & Resource Needs: New training, documentation structures, and possibly facility segmentation.
- Risk of Non‑Compliance: Companies unprepared for the regulatory separation risk inconsistent compliance across product categories.
____________________
The core impact of the 2026 updates to EudraLex Volume 4 – Annex 1 is the regulatory separation of human and veterinary GMP requirements.
Annex 1 continues to apply to human medicinal products. Beginning July 16, 2026, veterinary medicinal products must comply with newly established dedicated veterinary GMP regulations—not Annex 1.
This regulatory divergence directly affects manufacturing operations, compliance systems, audits, and quality management across the pharmaceutical industry.
____________________
Refer to the Current EU Annex 1
Get support from Rx-360’s Joint audit Program
____________________
Coming Soon: “How to Prepare for the EU’s New Approach to Regulated Veterinary Products”